UK NICE recommends use of Vimizim in mucopolysaccharidosis type 4A.
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Vimizim (elosulfase alfa), from BioMarin, for routine use in the NHS, treating mucopolysaccharidosis type 4A (MPS 4A) – a rare metabolic condition that primarily affects the skeleton.